Brief: Kiromic Biopharma Announces Company Will Directly Submit Amended Ind For Procel To The FDA In Second Half Of 2022
11/05/2022 11:59
May 11 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA ANNOUNCES COMPANY WILL DIRECTLY
SUBMIT AMENDED
IND FOR PROCEL™ TO THE FDA IN SECOND HALF OF 2022
* KIROMIC BIOPHARMA INC - TYPE A FDA MEETING WILL NOT BE
PURSUED
* KIROMIC BIOPHARMA INC - A TYPE A FDA MEETING WILL NOT BE
PURSUED
* KIROMIC BIOPHARMA INC - OVER COURSE OF LAST TEN MONTHS,
HAS
DEVELOPED A PLAN TO ADDRESS PREVIOUSLY OUTLINED CMC ISSUES
Source text for Eikon: ID:nBwbjZCJta
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site